Fragment 176-191: Dosage, Protocol, and Research Guide
Growth hormone fragment that promotes fat loss without affecting insulin sensitivity
Mechanism
C-terminal fragment of HGH that retains fat-burning properties without growth-promoting effects. Increases lipolysis through activation of beta-adrenergic receptors in adipose tissue.
Protocol at a glance
| Starting dose | 200mcg |
|---|---|
| Maintenance dose | 200-500mcg |
| Maximum dose | 500mcg |
| Frequency | 1-2 times daily |
| Typical duration | 8-12 weeks |
| Route | Subcutaneous |
| Injection site | Abdomen |
| Timing | On empty stomach, ideally before cardio |
Side effects
- Minimal reported side effects
Contraindications
- Pregnancy
- Active cancer
Protocol notes
- Derived from growth hormone C-terminus
- Promotes fat burning without muscle effects
- Take before cardio for best results
- No impact on insulin or glucose
- Specifically targets adipose tissue
Frequently asked questions
What is Fragment 176-191 and how does it work?
Fragment 176-191 is a synthetic peptide derived from the C-terminal portion of human growth hormone. It works by activating beta-adrenergic receptors in adipose tissue, promoting lipolysis (fat breakdown) without affecting muscle growth, insulin sensitivity, or systemic growth factors. Unlike full-length HGH, Fragment 176-191 retains only the fat-burning properties while eliminating growth-promoting effects, making it selective for adipose tissue metabolism.
What is the correct dosing for Fragment 176-191?
Standard research protocols for Fragment 176-191 call for doses between 200-500 micrograms per injection, administered 1-2 times daily. A common starting dose is 200mcg. The typical research cycle duration is 8-12 weeks. Administration is via subcutaneous injection in the abdominal region, preferably on an empty stomach before cardiovascular exercise for optimal effects.
Does Fragment 176-191 affect insulin or blood glucose?
No. Fragment 176-191 has no impact on insulin sensitivity or glucose metabolism. This is one of its distinguishing features—it specifically targets adipose tissue metabolism without affecting glucose regulation or insulin function, making it biochemically different from compounds that influence systemic carbohydrate handling.
What are the side effects of Fragment 176-191?
Available research indicates that Fragment 176-191 has minimal reported side effects. The favorable safety profile likely results from the peptide's targeted action on adipose tissue, which avoids many systemic effects associated with full-length growth hormone. However, individual responses can vary, and consulting a licensed physician before use is essential.
Can I stack Fragment 176-191 with other peptides?
Research on stacking protocols with Fragment 176-191 remains limited in published literature. The compound's selective action on adipose tissue suggests it may complement other metabolic research tools, but specific stacking protocols are not established. Any combination of research compounds should only be undertaken under the guidance of a qualified healthcare provider.
How long should I cycle Fragment 176-191?
Standard research cycles for Fragment 176-191 typically run 8-12 weeks. This duration allows sufficient time to observe metabolic changes in adipose tissue while maintaining a conservative approach to peptide exposure. Cycling—taking breaks between research periods—is a common practice in peptide research. Work with a healthcare provider to determine the appropriate cycle length for your research objectives.
Is Fragment 176-191 legal?
Fragment 176-191 is not FDA-approved for human use and is classified as a research chemical. Its legal status varies by jurisdiction, and it is not approved as a therapeutic agent in most countries. It is sold for research purposes only. Consult with a licensed physician and ensure compliance with local regulations before any use.
When should I inject Fragment 176-191 for best results?
Fragment 176-191 is most commonly administered on an empty stomach, ideally before cardiovascular exercise. This timing is intentional—beta-adrenergic receptor activation is naturally elevated during physical activity, which may enhance the peptide's fat-mobilizing effects. This suggests that aerobic exercise may complement Fragment 176-191 research protocols.
More GLP-1 & Weight Loss peptides · All peptide guides · Free dose calculator
Educational reference only — not medical advice. Work with a qualified clinician.